Antimicrobial resistance comparison of Klebsiella pneumoniae pathogens isolated from intra-abdominal and urinary tract infections in different organs, hospital departments and regions of China between 2014 and 2017
Autor: | Qiwen Yang, Jingjia Zhang, Yingchun Xu, Ge Zhang, Simeng Duan, Yang Yang, Dongxue Li, Hui Zhang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Microbiology (medical) China medicine.medical_specialty Imipenem medicine.drug_class Klebsiella pneumoniae Antibiotic resistance Cefepime 030106 microbiology Antibiotics Hospital Departments Microbial Sensitivity Tests Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Intra-abdominal infections Drug Resistance Bacterial medicine polycyclic compounds Humans Immunology and Allergy 030212 general & internal medicine Cross Infection General Immunology and Microbiology biology business.industry General Medicine Antimicrobial biology.organism_classification bacterial infections and mycoses Urinary tract infections female genital diseases and pregnancy complications QR1-502 Klebsiella Infections Community-Acquired Infections Infectious Diseases chemistry Carbapenems ESBL Amikacin Intraabdominal Infections business Ertapenem medicine.drug |
Zdroj: | Journal of Microbiology, Immunology and Infection, Vol 54, Iss 4, Pp 639-648 (2021) |
ISSN: | 1684-1182 |
Popis: | Background We describe antibiotic resistance trends of Klebsiella pneumoniae pathogens, responsible for urinary tract infections (UTIs) and intra-abdominal infections (IAIs), isolated from different organs and tissues, hospital departments and Chinese regions between 2014 and 2017. Methods Resistances of UTIs and IAIs derived K. pneumoniae isolates from 17 hospitals in 7 Chinese regions to amikacin, imipenem, piperacillin-tazobactam, ertapenem, and cefepime were unequivocally established. Results Overall resistance rates of K. pneumoniae IAI isolates obtained from gallbladder and abscesses increased to amikacin (14.29–30.95%) and for liver, gallbladder, and abscesses to imipenem (14.29–38.10%), piperacillin-tazobactam (23.81–38.10%), and ertapenem (23.81–38.10%) in 2017, but were constant (20–30%) for K. pneumoniae isolates from UTIs from 2014 to 2017. In medical and surgical ICUs, resistance rates to all tested antibiotics rose to ∼60% for IAIs, which was also reflected in higher resistance rates of hospital acquired (HA) compared to community acquired (CA) infections. In medical ICUs resistance rates increased to 50–60% for amikacin, imipenem, and ertapenem for UTI-derived K. pneumoniae isolates in 2017. Resistance rates to all tested antibiotics were highest in the east Jiangzhe region of China, being ∼60% for K. pneumoniae isolates from IAIs and 40% for K. pneumoniae isolates from UTIs to ertapenem and imipenem, as well as > 40% for piperacillin-tazobactam in 2017. Conclusion In China, ICUs resistance rates to K. pneumoniae IAIs and UTIs isolates was increased in 2017 for all tested antimicrobials including carbapenems, which makes them no longer suitable for empiric treatment. In the east Jiangzhe region this was a general trend that was independent of the type of hospital department. |
Databáze: | OpenAIRE |
Externí odkaz: |